The rise in ABT stock over the recent past can be attributed to an expected uptick in total procedures volume, aiding its medical devices business. Our detailed analysis of Abbott’s upside post-inflation shock captures trends in the company’s stock during the turbulent market conditions seen over 2022. Looking forward, diagnostics revenues are expected to see a decline in the near term, while the company’s other businesses, including medical devices and established pharmaceuticals, will likely see steady growth.